Rushi Potdar

Group Medical Director, Janssen US. Surgeon & business leader striving for cancer patients.
Nature lover. Usually skeptical yet curious. Tweets are my own.

[Rushi Potdar @rushi_md]

Congratulations to authors for publishing this deep dive data on #PSA kinetics in TITAN study of #apalutamide
in mHS #prostatecancer
Deep, rapid, and durable prostate-specific antigen decline with apalut... https://t.co/YX9CtUryNe

[Rushi Potdar @rushi_md]

@AmarUKishan @MSteinbergMD @UCLAJCCC @UCLA Congratulations!!

[Rushi Potdar @rushi_md]

ELCC2023 is fantastic. Good size conference, great data and a wonderful location (Copenhagen)! https://t.co/WaXfrhtlSZ

[Rushi Potdar @rushi_md]

Understanding potential DDIs #ProstateCancer drugs is important. Many THANKS to our authors and researchers on Apa-RP study for bringing this data to patients # Gordon Brown @Lash7587 @HafronJason # Daniel Saltzstein @NealShore2

[Targeted Oncology @TargetOncology]

Coadministration of #Apalutamide and #Relugolix in Patients with Localized #ProstateCancer at High Risk for Metastases https://t.co/p0uD5GArex #openaccess

[Rushi Potdar @rushi_md]

'urinary symptoms as indicator of #prostate cancer'...? NO!! @NHS The discrepancy baffles me when simple #prostatecancer screening exists. Great that @USPSTF got it right this time 👍
https://t.co/4S1M3vX502 via @urologytimes

[Rushi Potdar @rushi_md]

5 min read! fantastic recap of the #ESMO22 PRESTO data in BCR #prostatecancer by Dr Aggarwal
https://t.co/ueI8YUHBrv via @urotoday @ALLIANCE_org

[Rushi Potdar @rushi_md]

Great way to ‘walk-that-talk’ for #prostatecancer with @ZEROCancer Philadelphia 5K Run/Walk! Thank you to all who showed up to support the cause including colleagues from @JanssenUS colleagues and many esteemed medical professionals @MidAtlanticUro1 #CancerResearch

[Rushi Potdar @rushi_md]

@arvinkgeorge @AbhinavSidana What a dynamic duo!

[Rushi Potdar @rushi_md]

This was a No-Brainer !!🙂 thank you, NIH
NIH launches the next stage of its ‘human genome project’ for the brain https://t.co/LJNsNY0I4M via @statnews #research #brainhealth @NIH

[Rushi Potdar @rushi_md]

Genomic test shows higher proportion of black patients with prostate cancer reclassified to elevated risk groups. Congratulations researchers for helping bridge cancer disparity! @Decipher_VCYT @OUPAcademic @JNCI_Now #ProstateCancer #Disparity
https://t.co/kzUCYRsGqu

[Rushi Potdar @rushi_md]

What a great way to "Talk the Talk" with Shannon Sharpe revealing his prostate cancer diagnosis and his journey of triumph! RESPECT!!
https://t.co/WYWbN3yWvS
@ShannonSharpe #ProstateCancer @ZEROCancer @RAPCancer @ThePCRI

[ZERO Prostate Cancer @ZEROCancer]

We’re excited to debut a new episode of our #ProstateCancer Uncensored podcast, featuring NBA all-star @realgranthill33! Tune in to hear about Grant’s efforts to spread awareness and the message that EARLY DETECTION SAVES LIVES! 🏀 💙

Listen at https://t.co/TCLVIJxRGm.

[Rushi Potdar @rushi_md]

2021 Janssen U.S. Transparency Report is out.
Net prices declining by -2.8%, & ~ -17% compounded over the last six years say it all !!
R&D spend of ~$12 B is 100% > of Sales & Marketing spend #pharmaceuticals #innovation @JannsenUS @JNJNews
https://t.co/EMBHeQg5fU

[Rushi Potdar @rushi_md]

So proud of our research collab. w @ALLIANCE_org bringing new data for patients w high-risk biochemically recurrent #prostatecancer #PRESTO shows improved PSA PFS w apalutamide+ADT vs. ADT alone @morr316 #ESMO2022 @JanssenOncUS #RahulAggarwal @myESMO
https://t.co/YBXNpw3Ibj

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in @TheLancetOncol 👉1st study (GALAHAD study) to show efficacy of niraparib in men with mCRPC #prostatecancer with DNA repair defects & prior Rx with NHTs & taxanes. ORR:34% in BRCA+, 10.6% non BRCA+. https://t.co/vTpYlY6ug1 @OncoAlert @MAWJNJ @EfstathiouEleni @urotoday

[Rushi Potdar @rushi_md]

@Daniel_J_George @IRONMANregistry @loreleimucci @DrPhilKantoff @ThePCCTC @Movember Love it! Both IRONMAN and Real World Evidence network are such fantastic initiatives. Just what the doctor ordered !!

[Grand Rounds Urology @GRUrology]

Congrats to our 1st place poster session winner at #IPCU2021! Molecular Determinants of Outcome for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) With Addition of Apalutamide (APA) or Placebo (PBO) to Androgen Deprivation Therapy (ADT) in TITAN
Presented by Rushi Potdar